Pharvaris (PHVS) Depreciation & Amortization (CF) (2020 - 2026)
Pharvaris (PHVS) reported Depreciation & Amortization (CF) of $122607.5 for Q1 2026, up 10.69% on a YoY basis from $110764.5 in Q1 2025, and little changed quarter-over-quarter from $122070.9 in Q4 2025.
Pharvaris (PHVS) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Pharvaris has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $122607.5 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 10.69% year-over-year to $122607.5; the trailing twelve-month figure through Mar 2026 stood at -$7.7 billion (down 168.31% YoY), and the FY2025 full-year result was $472659.9, up 62.0% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $122607.5, roughly flat from $122070.9 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $235.8 billion in Q2 2025, with the low at -$243.6 billion in Q3 2025.
- Historically, Depreciation & Amortization (CF) has averaged -$621.5 million across 5 years, with a median of $71038.9 in 2023.
- The largest YoY upside for Depreciation & Amortization (CF) was 356841850.47% in 2023 against a maximum downside of 345944944.87% in 2023.
- Pharvaris' Depreciation & Amortization (CF) stood at $47108.9 in 2022, then surged by 50.8% to $71038.9 in 2023, then jumped by 36.82% to $97197.3 in 2024, then grew by 25.59% to $122070.9 in 2025, then climbed by 0.44% to $122607.5 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $122607.5 (Q1 2026), $122070.9 (Q4 2025), and -$243.6 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 429,663.65 |
| 10 | Pharvaris | 28.66 Bn | 28.37 Bn | - | 122,607.51 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 122,607.51 |
| Mar 31, 2026 | 122,607.51 |
| Dec 31, 2025 | 122,070.92 |
| Dec 31, 2025 | 122,070.92 |
| Sep 30, 2025 | -243.55 Bn |
| Sep 30, 2025 | -243.55 Bn |
| Jun 30, 2025 | 235.82 Bn |
| Jun 30, 2025 | 235.82 Bn |
| Mar 31, 2025 | 110,764.48 |
| Mar 31, 2025 | 110,764.48 |
| Dec 31, 2024 | 97,197.30 |
| Dec 31, 2024 | 97,197.30 |
| Sep 30, 2024 | -148.29 Bn |
| Sep 30, 2024 | -148.29 Bn |
| Jun 30, 2024 | 145.41 Bn |
| Jun 30, 2024 | 145.41 Bn |
| Mar 31, 2024 | 72,085.54 |
| Mar 31, 2024 | 72,085.54 |
| Dec 31, 2023 | 71,038.93 |
| Dec 31, 2023 | 71,038.93 |